Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
POR encodes an endoplasmic reticulum membrane oxidoreductase with an FAD-binding domain and a flavodoxin-like domain. Additionally we are shipping POR Kits (17) and POR Proteins (12) and many more products for this protein.
Showing 10 out of 121 products:
Human Polyclonal POR Primary Antibody for ICC, IF - ABIN2482126
Riddick, Ding, Wolf, Porter, Pandey, Zhang, Gu, Finn, Ronseaux, McLaughlin, Henderson, Zou, Flück: NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. in Drug metabolism and disposition: the biological fate of chemicals 2012
Show all 3 references for ABIN2482126
Human Polyclonal POR Primary Antibody for ICC, IF - ABIN2482131
Jensen, Møller: Plant NADPH-cytochrome P450 oxidoreductases. in Phytochemistry 2010
Show all 3 references for ABIN2482131
Human Polyclonal POR Primary Antibody for ICC, IF - ABIN2482132
Flück, Tajima, Pandey, Arlt, Okuhara, Verge, Jabs, Mendonça, Fujieda, Miller: Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. in Nature genetics 2004
Show all 3 references for ABIN2482132
Chicken Polyclonal POR Primary Antibody for IHC, WB - ABIN2773843
Lee, Kim, Yoon, Lee: Cytochrome P450 system expression and DNA adduct formation in the liver of Zacco platypus following waterborne benzo(a)pyrene exposure: implications for biomarker determination. in Environmental toxicology 2014
Human Polyclonal POR Primary Antibody for IHC (p), WB - ABIN390416
Fukami, Nishimura, Homma, Nagai, Hanaki, Uematsu, Ishii, Numakura, Sawada, Nakacho, Kowase, Motomura, Haruna, Nakamura, Ohishi, Adachi, Tajima, Hasegawa, Hasegawa, Horikawa, Fujieda, Ogata: Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients. in The Journal of clinical endocrinology and metabolism 2009
we observed that miR (show MLXIP Antibodies)-378 modulates the oscillation amplitudes of Cdkn1a (show CDKN1A Antibodies) in the control of cell cycle and Por in the regulation of oxidation reduction by forming partnership with different circadian transcription factors
Highest level of Rac1 activation was achieved on the smallest nanofibers, a trend that was lost in POR1 knockdown. This supports the hypothesis that on small nanofibers, POR1 binds to highly curved cell membranes, allowing Rac1 to dissociate and activate.
Results are the first to show that some forms of opioid-mediated stress-induced analgesia require brain neuronal P450 activity.
Immunological and metabolic changes resulting from a genetic deficiency in CPR (show GRID2 Antibodies) expression in the intestine in mice.
An apparent link exists between the cytochrome p450 reductase and FGF signaling pathways.
These data collectively indicate a novel role of the Cpr (show GRID2 Antibodies) gene in fear conditioning and memory.
this study provides novel insights into the regulation of gap junction function by CYPOR and suggests that Cx43 (show GJA1 Antibodies) may play an important role(s) in CYPOR-mediated bone defects seen in patients.
inactivation of the hepatic cytochrome P450 (show CYP Antibodies) system by conditional deletion of this enzyme
Changes in hepatic mRNA expression using microarray analysis and real-time PCR in POR null mice are reported.
POR function is indispensable for the proper regulation of retinoic acid levels and tissue distribution not only during early embryonic development but also in later morphogenesis and molecular patterning of the brain, abdominal/caudal (show CAD Antibodies) region and limbs.
NADPH-P450 reductase (NPR) was purified from hepatic microsomes of Xenopus laevis.
POR*28 does not significantly influence Tac (show IL2RA Antibodies) pharmacokinetic parameters.
the POR g.6593A>G polymorphism significantly influences CYP2B6 (show CYP2B6 Antibodies) activity
P450 (Cytochrome) Oxidoreductase Gene (POR) Common Variant (POR*28) Significantly Alters CYP2C9 (show CYP2C9 Antibodies) Activity in Swedish, But Not in Korean Healthy Subjects
POR A503V might decrease the risk of bladder cancer by reducing its metabolic activity.
POR besides CYP2B6 (show CYP2B6 Antibodies) can influence cyclophosphamide metabolism
Study is a thorough structural, dynamic, and thermodynamic characterization of the soluble form of human microsomal CPR using small-angle x-ray scattering and nuclear magnetic resonance spectroscopy under various conditions
This study confirmed that CYP3A5 (show CYP3A5 Antibodies)*1 was associated with lower tacrolimus trough concentrations. POR*28 was associated with decreased tacrolimus trough concentrations although the effect was small possibly through enhanced CYP3A4 (show CYP3A4 Antibodies) enzyme activity.
electron transfer between mCPR (show ANAPC1 Antibodies) and aromatase (show CYP19A1 Antibodies)
POR is the main determinant of SN30000 sensitivity in 3 different genetic backgrounds. Head and neck squamous cell carcinomas showed heterogeneous POR expression. There may be a relationship between HPV status and hypoxia-activated prodrug sensitivity.
Results show that combining the CYP3A5 (show CYP3A5 Antibodies)*1, POR*28 and CYP3A4 (show CYP3A4 Antibodies)*22 genotypes allows partial differentiation of early tacrolimus dose requirements and the time to reach therapeutic target concentrations after transplantation.
This gene encodes an endoplasmic reticulum membrane oxidoreductase with an FAD-binding domain and a flavodoxin-like domain. The protein binds two cofactors, FAD and FMN, which allow it to donate electrons directly from NADPH to all microsomal P450 enzymes. Mutations in this gene have been associated with various diseases, including apparent combined P450C17 and P450C21 deficiency, amenorrhea and disordered steroidogenesis, congenital adrenal hyperplasia and Antley-Bixler syndrome.
, NADPH-cytochrome P450 oxidoreductase
, P450 reductase
, cytochrome P450 reductase
, cytochrome c reductase (NADPH)
, P450 (cytochrome) oxidoreductase
, NADPH--cytochrome P450 reductase-like
, ADP-ribosylation factor-interacting protein 2
, Arfaptin 2
, partner of RAC1
, ADP-ribosylation factor interacting protein 2 (arfaptin 2)
, partner of Rac1
, NADPH--cytochrome P450 reductase
, NADPH-P450 reductase
, NADPH-dependent cytochrome P450 reductase
, NADPH-cytochrome P450 reductase
, NADPH-cytochrome P-450 oxidoreductase
, NADH cytochrome P450 oxydoreductase